Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics.

Annapaola Prestia; Anna Caroli; Sara K Wade; Wiesjie M van der Flier; Rik Ossenkoppele; Bart Van Berckel; Frederik Barkhof; Charlotte E Teunissen; Anders Wall; Stephen F Carter; Michael Schöll; Il Han Choo; Agneta Nordberg; Philip Scheltens; Giovanni B Frisoni

doi:10.1016/j.jalz.2014.12.001

Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics.

Annapaola Prestia, Anna Caroli, Sara K Wade, Wiesjie M van der Flier, Rik Ossenkoppele, Bart Van Berckel, Frederik Barkhof, Charlotte E Teunissen, Anders Wall, Stephen F Carter, Michael Schöll, Il Han Choo, Agneta Nordberg, Philip Scheltens, Giovanni B Frisoni

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Proposed diagnostic criteria (international working group and National Institute on Aging and Alzheimer's Association) for Alzheimer's disease (AD) include markers of amyloidosis (abnormal cerebrospinal fluid [CSF] amyloid beta [Aβ]42) and neurodegeneration (hippocampal atrophy, temporo-parietal hypometabolism on [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET), and abnormal CSF tau). We aim to compare the accuracy of these biomarkers, individually and in combination, in predicting AD among mild cognitive impairment (MCI) patients. METHODS: In 73 MCI patients, followed to ascertain AD progression, markers were measured. Sensitivity and specificity, positive (LR+) and negative (LR-) likelihood ratios, and crude and adjusted hazard ratios were computed. RESULTS: Twenty-nine MCI patients progressed and 44 remained stable. Positivity to any marker achieved the lowest LR- (0.0), whereas the combination Aβ42 plus FDG-PET achieved the highest LR+ (6.45). In a survival analysis, positivity to any marker was associated with 100% conversion rate, whereas negativity to all markers was associated with 100% stability. CONCLUSIONS: The best criteria combined amyloidosis and neurodegeneration biomarkers, whereas the individual biomarker with the best performance was FDG-PET.

Original language	English
Journal	Alzheimer's & dementia : the journal of the Alzheimer's Association
DOIs	https://doi.org/10.1016/j.jalz.2014.12.001
Publication status	Published - 31 Jan 2015

Keywords

Alzheimer's disease
Diagnostic accuracy
Diagnostic criteria
MCI
MRI
PET

Access to Document

10.1016/j.jalz.2014.12.001

Cite this

Prestia, A., Caroli, A., Wade, S. K., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A., Carter, S. F., Schöll, M., Choo, I. H., Nordberg, A., Scheltens, P., & Frisoni, G. B. (2015). Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1016/j.jalz.2014.12.001

@article{03cd64e99ef14ceb838630a3dbc46000,

title = "Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics.",

abstract = "BACKGROUND: Proposed diagnostic criteria (international working group and National Institute on Aging and Alzheimer's Association) for Alzheimer's disease (AD) include markers of amyloidosis (abnormal cerebrospinal fluid [CSF] amyloid beta [Aβ]42) and neurodegeneration (hippocampal atrophy, temporo-parietal hypometabolism on [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET), and abnormal CSF tau). We aim to compare the accuracy of these biomarkers, individually and in combination, in predicting AD among mild cognitive impairment (MCI) patients. METHODS: In 73 MCI patients, followed to ascertain AD progression, markers were measured. Sensitivity and specificity, positive (LR+) and negative (LR-) likelihood ratios, and crude and adjusted hazard ratios were computed. RESULTS: Twenty-nine MCI patients progressed and 44 remained stable. Positivity to any marker achieved the lowest LR- (0.0), whereas the combination Aβ42 plus FDG-PET achieved the highest LR+ (6.45). In a survival analysis, positivity to any marker was associated with 100% conversion rate, whereas negativity to all markers was associated with 100% stability. CONCLUSIONS: The best criteria combined amyloidosis and neurodegeneration biomarkers, whereas the individual biomarker with the best performance was FDG-PET.",

keywords = "Alzheimer's disease, Diagnostic accuracy, Diagnostic criteria, MCI, MRI, PET",

author = "Annapaola Prestia and Anna Caroli and Wade, {Sara K} and {van der Flier}, {Wiesjie M} and Rik Ossenkoppele and {Van Berckel}, Bart and Frederik Barkhof and Teunissen, {Charlotte E} and Anders Wall and Carter, {Stephen F} and Michael Sch{\"o}ll and Choo, {Il Han} and Agneta Nordberg and Philip Scheltens and Frisoni, {Giovanni B}",

year = "2015",

month = jan,

day = "31",

doi = "10.1016/j.jalz.2014.12.001",

language = "English",

journal = "Alzheimer's & dementia : the journal of the Alzheimer's Association",

issn = "1552-5279",

publisher = "Elsevier BV",

}

Prestia, A, Caroli, A, Wade, SK, van der Flier, WM, Ossenkoppele, R, Van Berckel, B, Barkhof, F, Teunissen, CE, Wall, A, Carter, SF, Schöll, M, Choo, IH, Nordberg, A, Scheltens, P & Frisoni, GB 2015, 'Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics.', Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1016/j.jalz.2014.12.001

TY - JOUR

T1 - Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics.

AU - Prestia, Annapaola

AU - Caroli, Anna

AU - Wade, Sara K

AU - van der Flier, Wiesjie M

AU - Ossenkoppele, Rik

AU - Van Berckel, Bart

AU - Barkhof, Frederik

AU - Teunissen, Charlotte E

AU - Wall, Anders

AU - Carter, Stephen F

AU - Schöll, Michael

AU - Choo, Il Han

AU - Nordberg, Agneta

AU - Scheltens, Philip

AU - Frisoni, Giovanni B

PY - 2015/1/31

Y1 - 2015/1/31

N2 - BACKGROUND: Proposed diagnostic criteria (international working group and National Institute on Aging and Alzheimer's Association) for Alzheimer's disease (AD) include markers of amyloidosis (abnormal cerebrospinal fluid [CSF] amyloid beta [Aβ]42) and neurodegeneration (hippocampal atrophy, temporo-parietal hypometabolism on [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET), and abnormal CSF tau). We aim to compare the accuracy of these biomarkers, individually and in combination, in predicting AD among mild cognitive impairment (MCI) patients. METHODS: In 73 MCI patients, followed to ascertain AD progression, markers were measured. Sensitivity and specificity, positive (LR+) and negative (LR-) likelihood ratios, and crude and adjusted hazard ratios were computed. RESULTS: Twenty-nine MCI patients progressed and 44 remained stable. Positivity to any marker achieved the lowest LR- (0.0), whereas the combination Aβ42 plus FDG-PET achieved the highest LR+ (6.45). In a survival analysis, positivity to any marker was associated with 100% conversion rate, whereas negativity to all markers was associated with 100% stability. CONCLUSIONS: The best criteria combined amyloidosis and neurodegeneration biomarkers, whereas the individual biomarker with the best performance was FDG-PET.

AB - BACKGROUND: Proposed diagnostic criteria (international working group and National Institute on Aging and Alzheimer's Association) for Alzheimer's disease (AD) include markers of amyloidosis (abnormal cerebrospinal fluid [CSF] amyloid beta [Aβ]42) and neurodegeneration (hippocampal atrophy, temporo-parietal hypometabolism on [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET), and abnormal CSF tau). We aim to compare the accuracy of these biomarkers, individually and in combination, in predicting AD among mild cognitive impairment (MCI) patients. METHODS: In 73 MCI patients, followed to ascertain AD progression, markers were measured. Sensitivity and specificity, positive (LR+) and negative (LR-) likelihood ratios, and crude and adjusted hazard ratios were computed. RESULTS: Twenty-nine MCI patients progressed and 44 remained stable. Positivity to any marker achieved the lowest LR- (0.0), whereas the combination Aβ42 plus FDG-PET achieved the highest LR+ (6.45). In a survival analysis, positivity to any marker was associated with 100% conversion rate, whereas negativity to all markers was associated with 100% stability. CONCLUSIONS: The best criteria combined amyloidosis and neurodegeneration biomarkers, whereas the individual biomarker with the best performance was FDG-PET.

KW - Alzheimer's disease

KW - Diagnostic accuracy

KW - Diagnostic criteria

KW - MCI

KW - MRI

KW - PET

U2 - 10.1016/j.jalz.2014.12.001

DO - 10.1016/j.jalz.2014.12.001

M3 - Article

C2 - 25646957

SN - 1552-5279

JO - Alzheimer's & dementia : the journal of the Alzheimer's Association

JF - Alzheimer's & dementia : the journal of the Alzheimer's Association

ER -

Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics.

Abstract

Keywords

Access to Document

Fingerprint

Cite this